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C-reactive protein (CRP), the classic marker of acute-
phase response, is an indicator of a variety of pathologic
processes, including infections, tissue damage, and
chronic inflammatory diseases (1, 2). The majority of
more than 15 well-conducted prospective studies in ini-
tially healthy individuals have shown a strong and inde-
pendent association between concentrations of CRP
within the reference interval (5 mg/L) and future major
cardiovascular events (3 ), although in some of them, no
such association could be established (4–7). The summary
estimate of the relative risk in formal metaanalysis was 2.0
(95% confidence interval, 1.6–2.5) (3 ). Furthermore, CRP
has been shown to add to risk prediction beyond and
above established cardiovascular risk factors (8 ). On the
basis of data from the Physicians’ Health Study and the
Nurses’ Health Study, an algorithm for risk assessment of
future coronary events that combines both CRP concen-
tration and the ratio of total cholesterol to HDL-choles-
terol has recently been proposed (9 ).
Because atherosclerosis represents a low-grade inflam-
matory process in the vascular bed, high-sensitivity (hs)
assays are needed when using circulating CRP concentra-
tions for risk prediction in cardiovascular diseases. Such
assays have been developed and are now commercially
available (10, 11). However, before screening of individ-
uals at risk can be recommended, CRP distributions in
apparently healthy adults in the general population must
be known. Such information is scarce. Furthermore, in
previous reports, women using oral contraceptives or
receiving hormone replacement therapy (HRT), both of
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which have been shown to significantly increase CRP
concentrations, had not been excluded (12–15). In this
report, we describe the frequency distribution of CRP
concentrations in 13 527 adult men and women from
different representative populations in Western Europe.
Furthermore, for one area [the MONICA (Monitoring
Trends and Determinants in Cardiovascular Disease)
project in Augsburg], data from four surveys at 5-year
intervals were available, thus providing information on
potential CRP changes in the same population over time.
Seven cross-sectional samples, each randomly drawn
from the general population of four different geographic
areas in former West Germany, France, and Scotland
(total of 16 945 men and women), were examined. The
VERA (Verbundstudie Erna¨hrungserhebung und Risiko-
faktoren Analytik) sample, representative of former West
Germany in 1987–1988, consisted of 862 men and 1144
women 18–88 years of age. Also in Germany, the Augs-
burg surveys were performed in 1984–1985 (1074 men;
ages 45–64 years), 1989–1990 (1550 men; 45–74 years),
1994–1995 (2450 men and 2451 women; 25–74 years), and,
in the framework of the KORA (Kooperative Gesund-
heitsforschung in der Region Augsburg) program, in
1999–2000 (2090 men and 2171 women; 25–74 years). The
MONICA Lille (France) survey of 1994–1995 consisted of
601 men and 594 women, ages 35–65 years, randomly
selected from the general population. Finally, the
MONICA north Glasgow survey of 1992 consisted of 928
men and 1030 women, ages 25–74 years. After the exclu-
sion of women on oral contraceptives or HRT and of
individuals with missing values for any variable, 13 527
participants remained for distribution analyses. Addi-
tional study details have been published elsewhere
(10, 16, 17). All serum/plasma samples were immediately
stored after collection and frozen at 70 to 90 °C until
analysis.
CRP was determined in these populations by two
different methods. A sensitive solid-phase monoclonal-
polyclonal IRMA with a range of 0.05–10.0 mg/L was
used for all samples except for the MONICA/KORA
Augsburg survey 1999–2000 and for the Glasgow
MONICA survey 1992. Method details have been de-
scribed elsewhere (10 ). The intraassay CVs ranged from
5.6% for the 0.50 mg/L calibrator to 1.4% for the 0.10
mg/L calibrator; the interassay CVs ranged between 8.0%
for the 0.5 mg/L calibrator and 0.5% for the 0.10 mg/L
calibrator. All samples with values exceeding the upper
limit of the assay range, i.e., 10 mg/L, were reassayed at
appropriately higher sample dilutions. CRP concentra-
tions in the MONICA/KORA Augsburg sample 1999–
2000 and in the Glasgow MONICA sample 1992 were
measured by a particle-enhanced immunonephelometric
assay performed on a BN II Analyzer (Dade Behring) (11 ).
The interassay CVs were 6% for both samples. There
was no difference in CRP measurements between serum
and plasma samples. Validation analyses between the two
methods have been performed in a sample of 792 men and
women from a case-control study (18 ). Comparisons
according to Bland and Altman (19 ) after log-transforma-
tion of CRP concentrations gave a mean difference be-
tween the IRMA and the BN II of 0.11 with 95% limits of
agreement of 1.17 and 0.95, indicating excellent agree-
ment between the two methods. The Spearman rank
correlation coefficient was 0.87 (unpublished data).
In all samples, CRP concentrations were highly skewed
to the right among both men and women. There was a
trend to higher CRP values with increasing age in all
samples. Median CRP values for men and women, the
latter not taking oral contraceptives or HRT, up to 44
years of age were 0.6–1.1 mg/L among the seven samples,
and among those 45 years of age and older, the median
CRP values were 1.2–1.7 mg/L (Table 1). Slight differ-
ences between CRP medians in the samples could mainly
be explained by the somewhat different age ranges cov-
ered, above and below the cutpoints of 45 years. Distri-
butions of CRP were comparable between men and
women among the different geographic areas studied and
were stable over time in the MONICA Augsburg samples
(men 45 years and above, 1.6–1.7 mg/L). Fewer than 5%
of men and women had CRP 10 mg/L, indicating an
ongoing high-grade inflammatory process, such as acute
infection. However, a remarkable subsample of up to
one-third of individuals had CRP concentrations 3
mg/L, which has been shown in several studies to be
associated with an increased risk for future cardiovascu-
lar events (20 ).
We have described frequency distributions of hs-CRP
in seven cross-sectional samples randomly selected from
the adult general population of three European countries
(Germany, France, and Scotland). Data sets included both
genders, excluded women on oral contraceptives or HRT,
and covered a wide age range. Furthermore, we looked
for potential changes of CRP over time in the MONICA
Augsburg samples covering a time period of15 years. In
all samples, CRP distributions were highly skewed to the
right, increased with age, and were similar in adult men
and in women who neither used oral contraceptives nor
received HRT. In addition, CRP concentrations in the
general population did not substantially differ among the
geographic areas studied and were stable over time.
On the basis of the risk prediction for cardiovascular
endpoints associated with increased CRP (3, 21, 22), mea-
suring this biomarker has recently been suggested as an
additional tool for risk stratification (9 ). However, a new
risk marker of disease needs to fulfill several require-
ments (23 ). It should show high sensitivity and specificity
and low intraindividual variability but high interindi-
vidual variation. For CRP, sensitive and robust methods
are commercially available (11 ). However, although CRP
represents an extremely sensitive marker of the acute-
phase response, it is completely unspecific and is influ-
enced by a variety of disease states, including infections,
rheumatic diseases, and malignancies among others (24 ).
Frequency distributions of a marker designated for risk
assessment in the general population are inevitably re-
quired for identifying individuals at increased risk. For
CRP, such reports are scarce, and, to the best of our
knowledge, no data from European countries exist from
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which women on oral contraceptives or HRT have been
excluded. Median CRP concentrations in these samples
are comparable to those reported from other populations
(25, 26). Furthermore, CRP distributions among men and
women not receiving hormones are very similar; thus,
sex-specific cutpoints for risk stratification are not needed.
Moreover, CRP concentrations in regions from three Eu-
ropean countries with different social status and lifestyle
habits are remarkably consistent.
The present analysis has several limitations. Only single
measurements were performed, which may not reflect the
true long-term values for the respective individuals; and
we studied only Caucasians. We did not exclude individ-
uals with diseases that might have affected CRP concen-
trations because this would have led to a selection bias
that could have affected the generalizability of our results.
However, the numbers of such persons were small in all
of the samples. Serum/plasma samples from all partici-
pants had been stored immediately after collection at 70
to 90 °C for up to 12 years. CRP is known to be a very
stable protein, and in one study (27 ), no significant
change was seen in CRP concentrations of samples stored
at 4 °C for 5 months and at 20 °C for up to 25 months.
Our own data from measurements of pooled samples
over a period of 5 years also showed no systematic shift
(unpublished data). Our analyses also have several
strengths. The two hs-CRP assays that we used showed
excellent agreement and were standardized according to
the WHO reference standard (85/506) (28 ). Finally, the
examined populations were representative of the general
population in three Western European countries.
Unsolved issues remain relating to the fact that, despite
similarities in its distribution, CRP has been shown to be
predictive for future cardiovascular events in various
populations with greatly differing absolute risks
(3, 29, 30). In addition, CRP distributions are comparable
between men and women, but cardiovascular risk is
clearly different between them. Finally, CRP concentra-
tions were stable over time although, e.g., data from the
MONICA project indicate a decrease in coronary heart
disease morbidity and mortality in several centers during
a 10-year period.
In summary, our data describing CRP concentrations in
representative populations may be useful for the clinician
and the general practitioner in assessing the risk of future
cardiovascular events by means of hs-CRP.
Table 1. CRP distributions in various European populations.
Gender
Age,
years n
Percentile
5 10 20 25 33.3 40 50 60 66.6 75 80 90 95
MONICA Augsburg Survey
1984–1985
Men 45–64 990 0.3 0.4 0.6 0.7 0.9 1.1 1.6 2.2 2.8 3.8 4.6 6.8 10.1
MONICA Augsburg Survey
1989–1990
Men 45–74 1379 0.3 0.4 0.6 0.8 1.0 1.3 1.7 2.3 2.8 3.8 4.5 7.3 10.4
MONICA Augsburg Survey
1994–1995
Men 25–44 869 0.2 0.2 0.4 0.4 0.6 0.7 0.9 1.3 1.5 2.1 2.5 3.9 5.6
45–74 1424 0.3 0.4 0.7 0.8 1.0 1.2 1.6 2.0 2.4 3.3 4.0 6.5 8.6
Womena 25–44 624 0.1 0.2 0.3 0.4 0.5 0.5 0.7 1.0 1.2 1.7 2.2 4.1 6.9
45–74 1031 0.3 0.4 0.7 0.9 1.1 1.3 1.7 2.2 2.7 3.4 4.2 6.2 8.8
MONICA/KORA Survey
1999–2000
Men 25–44 800 0.2 0.2 0.3 0.4 0.5 0.6 0.7 1.0 1.2 1.6 2.0 3.4 5.5
45–74 1236 0.3 0.4 0.6 0.8 1.0 1.2 1.6 2.2 2.8 3.5 4.3 6.9 9.5
Womena 25–44 645 0.2 0.2 0.3 0.4 0.5 0.6 0.7 1.0 1.3 1.8 2.2 4.6 8.0
45–74 865 0.2 0.4 0.6 0.8 1.0 1.2 1.6 2.2 2.8 3.5 4.3 6.9 9.5
MONICA Glasgow Survey
1992
Men 25–44 158 0.2 0.2 0.2 0.2 0.4 0.5 0.8 0.9 1.1 1.4 1.7 3.2 6.3
45–74 256 0.3 0.4 0.5 0.7 0.9 1.1 1.4 1.9 2.3 3.3 3.8 6.2 8.6
Women 24–44 168 0.2 0.2 0.2 0.3 0.4 0.5 0.6 0.9 1.0 1.4 1.7 3.4 5.5
45–74 297 0.2 0.2 0.4 0.6 0.8 0.9 1.2 1.6 1.9 2.6 3.2 6.4 9.8
MONICA Lille Survey
1994–1995
Men 35–44 162 0.2 0.3 0.5 0.6 0.7 0.8 1.1 1.4 1.7 2.5 2.8 4.8 8.9
45–65 439 0.3 0.4 0.6 0.7 0.9 1.1 1.4 1.9 2.4 3.5 3.9 8.0 9.4
Womena 35–44 98 0.1 0.3 0.4 0.4 0.5 0.6 0.8 1.0 1.4 1.8 2.9 5.3 7.8
45–65 303 0.1 0.3 0.6 0.7 0.8 1.1 1.5 2.0 2.6 3.7 4.4 6.7 9.7
VERA Survey 1987–1988 Men 18–44 426 0.2 0.2 0.3 0.4 0.5 0.5 0.7 1.0 1.2 1.9 2.5 5.5 9.1
45–88 380 0.3 0.4 0.6 0.6 0.8 1.1 1.7 2.2 2.9 4.1 4.9 7.3 9.8
Womena 18–44 547 0.2 0.3 0.4 0.5 0.6 0.8 1.0 1.6 2.4 3.4 4.4 7.3 9.9
45–80 430 0.3 0.4 0.5 0.6 0.8 1.0 1.4 1.9 2.5 3.3 4.1 6.5 8.4
a Women on oral contraceptives or HRT were excluded.
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Responses to different drugs can vary widely among
different individuals as a result of genetic variations in
drug-metabolizing enzymes, transporters, receptors,
and/or other cofactors. The multidrug resistance 1
(MDR1) transporter, a well-characterized member of the
ATP-binding cassette superfamily, was shown to efflux a
wide variety of structurally and functionally unrelated
drugs, including anticancer, antiarrhythmic, antidepres-
sant, antipsychotic, and antiviral agents. The pharmaco-
genetics of the MDR1 multidrug transporter have recently
received much scientific attention. Several single-nucle-
otide polymorphisms (SNPs) have been identified in the
MDR1 gene; some occur only in specific ethnic groups,
whereas others occur in all ethnic groups but at signifi-
cantly different allele frequencies among the different
races [see Ref. (1 ) and references therein]. Nonetheless,
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